Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Regulatory News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Clinigen Group Plc

11 Sep 2017 09:35

RNS Number : 3575Q
Numis Securities Limited
11 September 2017
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Numis Securities Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Clinigen Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Financial Adviser to Clinigen Group Plc

(d) Date dealing undertaken:

08/09/2017

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes

Quantum Pharma Plc

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.1p ordinary

Purchase

46,200

1116.43 GBX

1116.43 GBX

0.1p ordinary

Sale

61,200

1121.00 GBX

1115.00 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

11/09/2017

Contact name:

Jessica Meta

Telephone number:

0207 260 1330

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERGGUCWBUPMURG
Date   Source Headline
4th Apr 20224:54 pmRNSForm 8.5 (EPT/RI)-Clinigen Group plc_Amend
4th Apr 20223:29 pmRNSForm 8.3 - [Clinigen Group plc/Triley Bidco Ltd]
4th Apr 20223:20 pmRNSForm 8.3 - Clinigen Group plc
4th Apr 20223:20 pmRNSForm 8.3 - Clinigen Group plc
4th Apr 202212:31 pmGNWForm 8.3 - Clinigen Group PLC
4th Apr 202211:46 amGNWForm 8.3 - AXA INVESTMENT MANAGERS: Clinigen Group Plc
4th Apr 202211:09 amRNSForm 8.5 (EPT/RI)- Clinigen Group plc
4th Apr 202210:59 amGNWHSBC Bank Plc - Form 8.5 (EPT/RI) - Clinigen Group PLC
4th Apr 202210:50 amRNSScheme Becomes Effective
4th Apr 20229:50 amRNSForm 8.5 (EPT/NON-RI) Clinigen Group plc
4th Apr 20229:19 amRNSForm 8.5 (EPT/RI) - Clinigen Group Plc
4th Apr 20227:30 amRNSSuspension - Clinigen Group PLC
1st Apr 20223:29 pmRNSForm 8.3 - Clinigen Group plc
1st Apr 20223:25 pmRNSForm 8.3 - Clinigen Group
1st Apr 20223:20 pmRNSForm 8.3 - Clinigen Group plc
1st Apr 20223:00 pmRNSForm 8.3 - Clinigen Group plc
1st Apr 20221:27 pmGNWForm 8.3 - Clinigen Group PLC
1st Apr 20221:09 pmRNSForm 8.5 (EPT/RI)-Clinigen Group plc
1st Apr 202210:59 amRNSForm 8.5 (EPT/NON-RI)-CLINIGEN GROUP PLC
1st Apr 202210:52 amGNWHSBC Bank Plc - Form 8.5 (EPT/RI) - Clinigen Group PLC
1st Apr 202210:22 amRNSForm 8.5 (EPT/RI) - Clinigen Group PLC
1st Apr 20229:56 amRNSForm 8.3 - Clinigen Group Plc
31st Mar 20225:52 pmRNSForm 8.5 (EPT/RI)- Clinigen Group plc Amend
31st Mar 20223:30 pmGNWForm 8.3 - Clinigen Group plc
31st Mar 20223:29 pmRNSForm 8.3 - Clinigen Group plc
31st Mar 20223:27 pmRNSForm 8.3 - Clinigen Group plc
31st Mar 20223:20 pmRNSForm 8.3 - Clinigen Group plc
31st Mar 202212:54 pmRNSCourt Sanction of Scheme of Arrangement
31st Mar 202212:52 pmGNWForm 8.3 - Clinigen Group PLC
31st Mar 202211:11 amRNSForm 8.3 - CLINIGEN GROUP PLC
31st Mar 202211:09 amGNWHSBC Bank Plc - Form 8.5 (EPT/RI) - Clinigen Group PLC
31st Mar 202210:48 amRNSForm 8.5 (EPT/RI)- Clinigen Group plc
31st Mar 202210:41 amRNSForm 8.5 (EPT/NON-RI) Clinigen Group plc
31st Mar 202210:10 amRNSForm 8.3 - Clinigen Group Plc
30th Mar 20225:30 pmRNSClinigen Group
30th Mar 20223:21 pmRNSForm 8.3 - Clinigen Group Plc
30th Mar 20223:20 pmRNSForm 8.3 - Clinigen Group plc
30th Mar 20222:42 pmRNSForm 8.3 - Clinigen Group Plc
30th Mar 20221:44 pmGNWForm 8.3 - Clinigen Group PLC
30th Mar 202211:45 amRNSForm 8.5 (EPT/NON-RI)- Clinigen Group plc
30th Mar 202211:37 amRNSForm 8.5 (EPT/RI)- Clinigen Group plc
30th Mar 202211:19 amGNWHSBC Bank Plc - Form 8.5 (EPT/RI) - Clinigen Group PLC
30th Mar 202210:49 amRNSForm 8.3 - Clinigen Group PLC
30th Mar 202210:35 amRNSForm 8.5 (EPT/NON-RI) Clinigen Group plc
30th Mar 202210:34 amRNSForm 8.3 - Clinigen Group Plc
29th Mar 20223:20 pmRNSForm 8.3 - Clinigen Group plc
29th Mar 20222:48 pmRNSForm 8.3 - Clinigen Group Plc
29th Mar 20222:43 pmRNSForm 8.3 -Clinigen Group plc
29th Mar 20221:30 pmBUSForm 8.3 - CLINIGEN GROUP PLC
29th Mar 202212:55 pmGNWForm 8.3 - Clinigen Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.